Henry Schein

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgicals, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial on a non-recourse basis, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Henry Schein reports solid Q4 performance and anticipates growth

Henry Schein's Q4 performance showcased growth amidst challenges, with a strategic focus on core margin expansion and strong performance in dental specialties. While facing challenges from declining PPE sales and supply chain issues, the company sees opportunities in stable dental markets and continued growth in operating income. Overall, the company remains optimistic about its outlook for 2023.

Henry Schein reports strong Q1 earnings, eyes growth through acquisitions

Henry Schein's Q1 2023 earnings call highlighted strong financial performance across its dental, medical, and Technology and Value-Added Services businesses. While facing challenges from declining PPE and COVID-19 test kit sales, the company remains optimistic about growth opportunities through acquisitions and stable business segments.

Henry Schein reports solid Q2 results, eyes growth opportunities

Henry Schein's Q2 performance was driven by strong dental sales, while facing challenges from declining PPE and COVID test kit sales. The company is focused on strategic acquisitions and expanding product offerings, with opportunities in technology and specialty products driving growth.

Henry Schein navigates post-cyber incident challenges, focuses on recovery

Henry Schein faced challenges from a cybersecurity incident impacting operations but showcased resilience and recovery efforts across its business segments.
Strategic initiatives focused on customer retention, operational efficiency, and cybersecurity response highlight the company's commitment to long-term growth and stability.
Despite challenges in specific segments and cybersecurity spending variables, Henry Schein's focus on recovery, cost-cutting, and customer trust positions it for future opportunities.
The company's emphasis on digital channels, stable medical demand, and strategic cost-cutting measures underscores its adaptability and strategic vision for sustained growth.

Henry Schein reports resilient Q4 performance and outlines 2024 guidance

Henry Schein's Q4 2023 performance reflects resilience amidst challenges, with a strategic focus on technology, global sales, and recovery post-cyber incident. The company's 2024 outlook includes managing residual cyber impacts and pursuing growth opportunities.

Henry Schein reports solid Q1 earnings, eyes market share expansion

Henry Schein's Q1 performance reflects resilience and growth across key segments, with a focus on market share expansion and profitability. While facing challenges in dental consumables and pricing stability, the company is leveraging opportunities in product portfolio expansion and market positioning. Strategic acquisitions and recovery efforts post-cyber incident are driving competitive strength and customer loyalty.

Henry Schein reports mixed Q2 performance, focuses on cost savings

Henry Schein navigated challenges from a cyber incident, with mixed performance across segments in Q2 2024.
Strong sales growth in dental specialties, focus on cost savings, and resilience in technology services were highlights.
The company's strategic initiatives, financial guidance update, and confidence in future prospects were key takeaways from the call.

Henry Schein excels in Q3 with strategic growth initiatives

Henry Schein's Q3 performance reflects strong market positioning and strategic execution, driving growth across key business segments.
While facing challenges such as LCI sales decline, the company's focus on operational efficiency and cost management remains a priority.
With increased sales guidance, ongoing restructuring initiatives, and strategic capital allocation plans, Henry Schein is poised for continued success and expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins. The Technology and Value-Added Services segment offers financial on a non-recourse basis, network, and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. reports fourth quarter 2020 financial results from continuing operations.

Henry Schein Reports Fourth Quarter 2020 Financial Results From Continuing Operations

AMERICAN FORK, Utah--(BUSINESS WIRE)--Henry Schein One Appoints Mike Baird as New Chief Executive Officer

Henry Schein One Appoints New Chief Executive Officer

Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Henry Schein (HSIC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. announced that Mohamad Ali and Deborah Derby have been appointed as members of the Company's Board of Directors.

Henry Schein Announces Two New Directors

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. to webcast fourth quarter and full-year 2020 conference call on Wednesday, February 17, 2021.

Henry Schein to Webcast Fourth Quarter and Full-Year 2020 Conference Call on Wednesday, February 17, 2021 at 10:00 A.M. ET

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. has been named to the FORTUNE® “World's Most Admired Companies” list for 2021, the 20th consecutive year it has been so honored.

Henry Schein Named to Fortune ‘World's Most Admired Companies' List for 20th Consecutive Year

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Earns Top Marks In Human Rights Campaign's 2021 Corporate Equality Index

Henry Schein Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index

Quest Diagnostics

Fresenius Medical Care

Invacare

Here are some dirt-cheap MedTech value stocks which are expected to provide long-term gains in 2021.

4 MedTech Underperformers Poised for a Turnaround in 2021

The developments are expected to strengthen Henry Schein's (HSIC) presence in high potential and still-untapped markets.

Henry Schein (HSIC) Grows Inorganically, Closes JV, Buys Stake

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. acquires majority interest in Prism Medical Products and enters the home medical supply market.

Henry Schein Acquires Majority Interest in Prism Medical Products, Enters Home Medical Supply Market

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. completes joint venture with Casa Schmidt to offer an expanded array of products and services to customers in Spain and Portugal.

Henry Schein Completes Joint Venture with Casa Schmidt

Colgate-Palmolive

CVS Health

GlaxoSmithKline

Johnson & Johnson

Procter & Gamble

DENTSPLY SIRONA

As the Covid-19 pandemic worsens, the case for dental stocks to buy might not seem too bright. However, this sector is a very broad one, with upside opportunities available right now.

8 Dental Stocks If You Want to Clean Up

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. will virtually present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 7:30 a.m. Eastern time.

Henry Schein to Present at the 39th Annual J.P. Morgan Healthcare Conference

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Medical, the U.S. Medical business of Henry Schein, Inc., today announced the availability of Ansell Healthcare Product's AlphaTec® Model 214 gowns to practitioners in North America. The availability of these gowns enables Henry Schein to help deliver greater access to Ansell's non-surgical isolation gowns, which feature durable DuPont™ Tyvek® 1222A fabric, and advanced chemical protection, helping to enhance the safety of front-line health care wor

Henry Schein Medical Enhances Access to Ansell Isolation Gowns Amid COVID-19, Helping to Improve the Safety of Front-Line Health Care Professionals

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Medical, the U.S. medical business of Henry Schein, Inc., recently entered into a distribution agreement with Yosi Health, a provider of digital patient scheduling, registration, payment, and communication cloud-based software solutions. For physicians and patients looking for a streamlined waiting room process, Yosi Health's patient intake solution, Yosi Intake, can create a contactless waiting room by enabling patients to register at home, helping

Henry Schein Medical Helps Automate and Streamline Patient Waiting Room Process With Yosi Health

Is Henry Schein (HSIC) a great pick from the value investor's perspective right now? Read on to know more.

Can Value Investors Henry Schein (HSIC) Stock Right Now?

Covetrus Inc

FactSet Research Systems

Merck

Nestle SA

Zoetis

More households own pets than have children, and they'll pay to keep their furry friends happy. Here are 6 big pet stocks.

85 Million & Climbing: Why Pets = Profits for These 6 Companies

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?

Henry Schein (HSIC) Up 7.5% Since Last Earnings Report: Can It Continue?

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Announces Virtual Presence at Greater New York Focused on 3D Imaging, 3D Printing, and CAD/CAM Solutions

Henry Schein Announces Virtual Presence at Greater New York Dental Meeting Focused on 3D Imaging, 3D Printing, and CAD/CAM Solutions

Henry Schein has had a period of sequential growth, fuelled entirely by Covid-related demand and PPE distribution. Covid exposure is an interesting factor for the company, presenting near-term tailwinds and headwinds, via product demand and patient volume volatility, respectively.

Henry Schein: Tailwinds And Headwinds From Covid-19; Near-Term Upside Only

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. announced that the Company will present at several virtual investor conferences in December.

Henry Schein Announces Participation in Upcoming Virtual Conferences in December

CALGARY, Alberta--(BUSINESS WIRE)-- #albertadentist--With businesses everywhere struggling to keep their doors open, one small firm has big reasons to celebrate. Stream Dental Staffing Solutions Ltd., aka Stream Dental HR and Henry Schein Canada, a wholly owned subsidiary of Henry Schein, Inc., (Nasdaq: HSIC), the world's largest provider of health care products and services to office-based dental and medical practitioners, have entered into an agreement for Stream Dental HR to be Henry Schein's provider of stra

Calgary Dental HR Firm Enters Agreement with Global Dental Supplier to Provide HR Management Services

Henry Schein, Inc.'s (HSIC) CEO Stanley Bergman on Q3 2020 Results - Earnings Call Transcript

Henry Schein, Inc. (HSIC) CEO Stanley Bergman on Q3 2020 Results - Earnings Call Transcript

Henry Schein (HSIC) sees robust segmental performance in Q3 boosted by strong rebound in sales and solid demand for PPE and COVID-19-related products.

News for Henry Schein Stock (HSIC)